JPWO2019200274A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019200274A5 JPWO2019200274A5 JP2021505625A JP2021505625A JPWO2019200274A5 JP WO2019200274 A5 JPWO2019200274 A5 JP WO2019200274A5 JP 2021505625 A JP2021505625 A JP 2021505625A JP 2021505625 A JP2021505625 A JP 2021505625A JP WO2019200274 A5 JPWO2019200274 A5 JP WO2019200274A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- kda
- item
- hyaluronic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Description
同等物
本発明の特定の実施形態を論じてきたが、上記の明細書は例示的なものであり、限定的なものではない。本発明の多くの変形は本明細書及び以下の特許請求の範囲を検討することにより、当業者に明らかになるのであろう。本発明の全範囲は、特許請求の範囲、それらの均等物の全範囲、及び明細書、並びにそのような変形を参照することによって決定されるべきである。
本発明は例えば以下の態様を含む。
［項１］
約50～約1000kDaの重量平均分子量(Mw)を有するヒアルロン酸又はその薬学的に許容される塩；及び
薬学的に許容される賦形剤
を含む医薬組成物。
［項２］
前記ヒアルロン酸が、約150kDaの重量平均分子量(Mw)を有する、項1に記載の医薬組成物。
［項３］
吸入に適した形態の、項1又は2に記載の医薬組成物。
［項４］
鼻腔内、肺内、気管内、気管支内、又は肺胞内投与に適した形態の、項1～3のいずれか1項に記載の医薬組成物。
［項５］
肺胞内投与に適した形態の、項4に記載の医薬組成物。
［項６］
乾燥粉末吸入器による投与に適した形態の、項1～5のいずれか1項に記載の医薬組成物。
［項７］
液体噴霧装置による投与に適した形態の、項1～5のいずれか1項に記載の医薬組成物。
［項８］
前記液体噴霧装置がエアロゾル装置である、項7に記載の医薬組成物。
［項９］
前記エアロゾル装置がネブライザー又は電気流体力学的エアロゾル装置である、項8に記載の医薬組成物。
［項１０］
項1～6のいずれか1項に記載の医薬組成物を含む吸入器。
［項１１］
約2μm～約3μmのサイズの液滴を送達するように構成された、項10に記載の吸入器。
［項１２］
約50～約1000kDaの重量平均分子量(Mw)を有するヒアルロン酸又はその薬学的に許容される塩を対象に投与することを含む、対象における弾性線維関連障害を治療するための方法。
［項１３］
前記ヒアルロン酸が、約150kDaの重量平均分子量(Mw)を有する、項12に記載の方法。
［項１４］
吸入によってヒアルロン酸を投与することを含む、項12又は13に記載の方法。
［項１５］
ヒアルロン酸を副鼻腔、肺系、気管、気管支、又は肺胞に投与することを含む、項12～14のいずれか1項に記載の方法。
［項１６］
弾性線維関連障害が、皮膚弛緩症、ウィリアムス症候群、アルファ-1アンチトリプシン欠損症、肺気腫、慢性閉塞性肺疾患(COPD)、肝疾患、ブシュケ-オレンドルフ症候群、メンケス病、弾性線維性仮性黄色腫、マルファン症候群、ハーラー病、高血圧又は先天性心臓欠陥である、項12～15のいずれか1項に記載の方法。
［項１７］
前記弾性線維関連障害がCOPDである、項16に記載の方法。
Equivalents Although specific embodiments of the present invention have been discussed, the above specification is exemplary and not limiting. Many variations of the invention will be apparent to those skilled in the art by examining the specification and the claims below. The entire scope of the invention should be determined by reference to the claims, the entire scope of their equivalents, and the specification, as well as such variations.
The present invention includes, for example, the following aspects.
[Item 1]
A pharmaceutical composition comprising hyaluronic acid or a pharmaceutically acceptable salt thereof having a weight average molecular weight (M w ) of about 50 to about 1000 kDa; and a pharmaceutically acceptable excipient.
[Item 2]
Item 2. The pharmaceutical composition according to Item 1, wherein the hyaluronic acid has a weight average molecular weight (M w ) of about 150 kDa.
[Item 3]
Item 2. The pharmaceutical composition according to Item 1 or 2, which is in a form suitable for inhalation.
[Item 4]
Item 6. The pharmaceutical composition according to any one of Items 1 to 3, which is in a form suitable for intranasal, intrapulmonary, tracheal, intrabronchial, or intraalveolar administration.
[Item 5]
Item 4. The pharmaceutical composition according to Item 4, which is in a form suitable for intra-alveolar administration.
[Item 6]
Item 6. The pharmaceutical composition according to any one of Items 1 to 5, which is in a form suitable for administration by a dry powder inhaler.
[Item 7]
Item 6. The pharmaceutical composition according to any one of Items 1 to 5, which is in a form suitable for administration by a liquid spray device.
[Item 8]
Item 6. The pharmaceutical composition according to Item 7, wherein the liquid spraying device is an aerosol device.
[Item 9]
Item 8. The pharmaceutical composition according to Item 8, wherein the aerosol device is a nebulizer or an electrohydrodynamic aerosol device.
[Item 10]
An inhaler containing the pharmaceutical composition according to any one of Items 1 to 6.
[Item 11]
Item 10. The inhaler according to Item 10, which is configured to deliver droplets having a size of about 2 μm to about 3 μm.
[Item 12]
A method for treating an elastic fiber-related disorder in a subject, comprising administering to the subject hyaluronic acid or a pharmaceutically acceptable salt thereof having a weight average molecular weight (M w ) of about 50 to about 1000 kDa.
[Item 13]
Item 12. The method according to Item 12, wherein the hyaluronic acid has a weight average molecular weight (M w ) of about 150 kDa.
[Item 14]
Item 12. The method according to Item 12 or 13, comprising administering hyaluronic acid by inhalation.
[Item 15]
12. The method of any one of Items 12-14, comprising administering hyaluronic acid to the sinuses, pulmonary system, trachea, bronchi, or alveoli.
[Item 16]
Elastic fiber-related disorders include cutis laxa, Williams syndrome, alpha-1 antitrypsin deficiency, emphysema, chronic obstructive pulmonary disease (COPD), liver disease, Buschke-Ollendorff syndrome, Menquez disease, elastic fibrous pseudoyellow tumor, The method according to any one of Items 12 to 15, which is Marfan syndrome, Harler's disease, hypertension or congenital heart defect.
[Item 17]
Item 16. The method according to Item 16, wherein the elastic fiber-related disorder is COPD.
Claims (18)
薬学的に許容される賦形剤
を含む医薬組成物。 A pharmaceutical composition comprising hyaluronic acid or a pharmaceutically acceptable salt thereof having a weight average molecular weight (M w ) of about 50 to about 1000 kDa; and a pharmaceutically acceptable excipient.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862656654P | 2018-04-12 | 2018-04-12 | |
| US62/656,654 | 2018-04-12 | ||
| PCT/US2019/027257 WO2019200274A1 (en) | 2018-04-12 | 2019-04-12 | Compositions and methods for treating elastic fiber breakdown |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021521280A JP2021521280A (en) | 2021-08-26 |
| JPWO2019200274A5 true JPWO2019200274A5 (en) | 2022-04-22 |
Family
ID=66323966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021505625A Pending JP2021521280A (en) | 2018-04-12 | 2019-04-12 | Compositions and Methods for Treating Elastic Fibrosis |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US10933084B2 (en) |
| EP (1) | EP3773614A1 (en) |
| JP (1) | JP2021521280A (en) |
| WO (1) | WO2019200274A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111265590B (en) * | 2020-01-21 | 2022-03-01 | 华熙生物科技股份有限公司 | Hyaluronic acid freeze-drying preparation for nasal spray and preparation method and application thereof |
| WO2023285984A1 (en) * | 2021-07-14 | 2023-01-19 | Redox-Co S.R.L. | Glutahtione c4 against airway affections |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA791659B (en) | 1978-04-17 | 1980-04-30 | Ici Ltd | Process and apparatus for spraying liquid |
| US4172896A (en) | 1978-06-05 | 1979-10-30 | Dainippon Pharmaceutical Co., Ltd. | Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same |
| GB8504253D0 (en) | 1985-02-19 | 1985-03-20 | Ici Plc | Electrostatic spraying apparatus |
| DE3815221C2 (en) | 1988-05-04 | 1995-06-29 | Gradinger F Hermes Pharma | Use of a retinol and / or retinoic acid ester-containing pharmaceutical preparation for inhalation for acting on the mucous membranes of the tracheo-bronchial tract, including the lung alveoli |
| GB9217295D0 (en) | 1992-08-14 | 1992-09-30 | Wellcome Found | Controlled released tablets |
| GB9225098D0 (en) | 1992-12-01 | 1993-01-20 | Coffee Ronald A | Charged droplet spray mixer |
| US6105571A (en) | 1992-12-22 | 2000-08-22 | Electrosols, Ltd. | Dispensing device |
| GB9315856D0 (en) | 1993-07-30 | 1993-09-15 | Wellcome Found | Stabilized pharmaceutical |
| US5541231A (en) | 1993-07-30 | 1996-07-30 | Glaxo Wellcome Inc. | Stabilized Pharmaceutical |
| US5358970A (en) | 1993-08-12 | 1994-10-25 | Burroughs Wellcome Co. | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
| GB9406171D0 (en) | 1994-03-29 | 1994-05-18 | Electrosols Ltd | Dispensing device |
| GB9406255D0 (en) | 1994-03-29 | 1994-05-18 | Electrosols Ltd | Dispensing device |
| GB9410658D0 (en) | 1994-05-27 | 1994-07-13 | Electrosols Ltd | Dispensing device |
| DK0814860T3 (en) | 1995-03-14 | 2000-05-08 | Siemens Ag | Ultrasonic nebulizer with removable precision metering unit |
| AU701843B2 (en) | 1995-03-14 | 1999-02-04 | Siemens Aktiengesellschaft | Removable precision dosating unit for ultrasonic atomizer device |
| WO1997039745A1 (en) | 1996-04-19 | 1997-10-30 | Sloan-Kettering Institute For Cancer Research | Use of inhaled retinoids in the prevention of cancer |
| NZ504021A (en) | 1997-10-17 | 2003-04-29 | Systemic Pulmonary Delivery Lt | Method and apparatus for delivering aerosolized medication having air discharged through air tube directly into plume of aerosolized medication |
| JP2002501892A (en) | 1998-01-29 | 2002-01-22 | セプラコア インコーポレーテッド | Pharmaceutical use of optically pure (-)-viewpropion |
| SI20413A (en) | 1998-03-16 | 2001-06-30 | Inhale Therapeutic Systems, Inc. | Aerosolized active agent delivery |
| EP1292314A2 (en) * | 2000-05-23 | 2003-03-19 | The Trustees of Columbia University in the City of New York | Method for treating respiratory disorders associated with pulmonary elastic fiber injury comprising the use of glycosaminoglycans |
| AU2002315330A1 (en) | 2001-06-15 | 2003-01-02 | Exhale Therapeutics, Inc. | Treatment of respiratory conditions associated with bronchoconstriction with aerosolized hyaluronic acid |
| DK1811987T3 (en) | 2004-11-18 | 2008-07-14 | Uni Pharma Kleon Tsetis Pharmaceutical Lab Sa | Dry powder comprising levothyroxine sodium administered via inhaler |
| EP2545925B1 (en) * | 2011-07-12 | 2018-02-14 | Holy Stone Healthcare Co.,Ltd. | Compositions comprising hyaluronic acid for treating and preventing mucosa related diseases |
-
2019
- 2019-04-12 WO PCT/US2019/027257 patent/WO2019200274A1/en active Application Filing
- 2019-04-12 US US16/383,033 patent/US10933084B2/en active Active
- 2019-04-12 JP JP2021505625A patent/JP2021521280A/en active Pending
- 2019-04-12 EP EP19720287.2A patent/EP3773614A1/en active Pending
-
2021
- 2021-02-25 US US17/185,482 patent/US20210177887A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dhanani et al. | Fundamentals of aerosol therapy in critical care | |
| US8263645B2 (en) | Disodium cromoglycate compositions and methods for administering same | |
| Ari et al. | Inhalation therapy in patients receiving mechanical ventilation: an update | |
| Moustafa et al. | Lung deposition and systemic bioavailability of different aerosol devices with and without humidification in mechanically ventilated patients | |
| Wildhaber et al. | Aerosol delivery to wheezy infants: a comparison between a nebulizer and two small volume spacers | |
| US7998463B2 (en) | Targeted delivery of lidocaine and other local anesthetics and a method for treatment of cough, asthma and tussive attacks | |
| US8709496B2 (en) | Use of deuterium oxide for the treatment of virus-based diseases of the respiratory tract | |
| US20150101597A1 (en) | Methods of treatment | |
| Madney et al. | Nebulizers and spacers for aerosol delivery through adult nasal cannula at low oxygen flow rate: an in-vitro study | |
| JP2008513444A (en) | Methods for targeted delivery of lidocaine and other local anesthetics and treatment of cough and cough attacks | |
| Dhand | Inhalation therapy with metered-dose inhalers and dry powder inhalers in mechanically ventilated patients | |
| Newman et al. | The nasal distribution of metered does inhalers | |
| JP2012505262A (en) | COPD and other lung disease treatment methods | |
| Kaur et al. | Advanced aerosol delivery devices for potential cure of acute and chronic diseases | |
| Calvert et al. | Enhanced delivery of nebulised salbutamol during non‐invasive ventilation | |
| de Pablo et al. | Nebulised antibiotherapy: conventional versus nanotechnology-based approaches, is targeting at a nano scale a difficult subject? | |
| JP2008502699A5 (en) | ||
| AU2024201359A1 (en) | Antiarrhythmic formulation | |
| US20210177887A1 (en) | Compositions and methods for treating elastic fiber breakdown | |
| JP2008502698A5 (en) | ||
| JPWO2019200274A5 (en) | ||
| KR20220137051A (en) | 5-amino-2,3-dihydro-1,4-phthalazinedione for inhalation treatment of inflammatory lung disease | |
| US20220218686A1 (en) | Antiarrhythmic formulation | |
| US20220202700A1 (en) | Compositions for the treatment of viral pulmonary infections | |
| CA2872569C (en) | Uses of antagonists of hyaluronan signaling |